Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials

Urology

Volumn 48, Issue 3, 1996, Pages 398-405

  Boyle, Peter ^a   Gould, A Lawrence ^b   Roehrborn, Claus G ^b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; META ANALYSIS; ORGAN SIZE; PREDICTION; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; SYMPTOMATOLOGY; TREATMENT OUTCOME; URINE FLOW RATE;

EID: 0030249241     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00353-6     Document Type: Article

References (35)

1. Bartsch G, Muller HR, Oberholzer M, and Rohr HP: Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol 122: 487-491, 1979.
2. Shapiro E, Haratano V, and Lepor H: The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate 22: 297-302, 1992.
3. Boyle P, McGinn R, Maisonneuve P, and La Vecchia C: Epidemiology of benign prostatic hyperplasia: present knowledge and studies needed. Eur Urol 20: 3-10, 1991.
4. Sagnier PP, Girman CJ, Garraway M, Kumamoto Y, Lieber MM, Richard F, MacFarlane G, Guess HA, Jacobsen SJ, and Tsukamoto T, et al: International comparison of the community prevalence of symptoms of prostatism in four countries. Eur Urol 29: 15-20, 1996.
5. Boyle P, Maisonneuve P, and Steg A: Decrease in mortality from benign prostatic hyperplasia: a major unheralded health triumph. J Urol 155: 176-180, 1996.
6. McConnell JD: The pathophysiology of benign prostatic hyperplasia. J Androl 12: 356-363, 1991.
7. Walsh PC, Hutchins GH, and Ewing LL: Tissue content of dihydrotestosterone in human prostatic hyperplasia is not supranormal. J Clin Invest 72: 1772-1777, 1983.
8. Wilkin RP, Bruchovsky N, Rennie PS, and Comeau T: Stromal localization of testosterone 5α-reductase in normal, hyperplastic and carcinomatous prostates. Proc Am Assoc Cancer 20: 419, 1979.
9. Brooks JR, Liang T, and Rasmusson GH: A new class of Δ4-5α-reductase inhibitors. Arch Andrology 9: 56, 1982.
10. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh P, McConnell J, Andriole GL, Geller J, Bracken BR, and Tenover JS, et al: The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 327: 1185-1191, 1992.
11. The Finasteride Study Group: Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 22: 291-299, 1993.
12. Andersen JT, Ekman P, Wolf H, Beisland HO, Johansson JE, Kontturi M, Lehtonen T, Tveter K, and the Scandinavian BPH Study Group: Can finasteride reverse the progress of benign prostatic hyperplasia? A two year placebo-controlled study. Urology 46: 631-637, 1995.
13. Beisland HO, Binkowitz B, Brekkan E, Ekman P, Konturri M, Lehtonen T, Lundmo P, Pappas F, Round E, and Shapiro D, et al: Scandinavian clinical study of finasteride in the treatment of benign prostatic hyperplasia. Eur Urol 22: 271-277, 1992.
14. Stoner E: Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 43: 284-294, 1994.
15. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley GJ, Haakenson C, Machi M, Narayan P, and Padley R: A randomized, placebo-controlled clinical trial of the safety and efficacy of terazosin and finasteride monotherapy and terazosin/finasteride combination therapy in men with clinical benign prostate hyperplasia: a Department of Veterans Affairs Cooperative Study (abstract 1105). J Urol 155: 587A, 1996.
16. Cockett ATK, Aso Y, Denis L, Murphy G, Khoury S, Abrams P, Barry M, Carlton GE, Fitzpatrick J, and Gibbons R, et al: Recommendations of the International Consensus Committee. The 2nd International Consultation on Benign Prostatic Hyperplasia (BPH). Channel Island, Scientific Communication International, Ltd., 1993, pp 553-564.
17. McConnell JD, Barry MJ, Bruskewitz RC, Bueschen AJ, Denton SE, Holtgrewe HL, Lange JL, McClennan BL, Mebust WK, and Reilly NJ, et al: Benign prostatic hyperplasia; diagnosis and treatment. Clinical Practice Guideline, Number 8. Rockville, Md, Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, February 1994.
18. Rahmouni A, Yang A, Tempany CM, Frenkel T, Epstein J, Walsh P, Leichner PK, Ricci C, and Zerhouni E: Accuracy of in-vivo assessment of prostate volume by MRI and transrectal ultrasonography. J Comput Assist Tomogr 16: 935-940, 1992.
19. Al-Rimawi M, Griffiths DJ, Boake RC, Mador DR, and Johnson MA: Transrectal ultrasound versus magnetic resonance imaging in the estimation of prostate volume. Br J Urol 74: 596-600, 1994.
20. Hricak H, Jeffrey RB, Dooms GC, and Tanagho EA: Evaluation of prostate size: a comparison of ultrasound and magentic resonance imaging. Urol Radiol 9: 1-8, 1987.
21. Maritz JS, and Lwin T: Empirical Bayes Methods, 2nd ed. New York, Chapman and Hall, 1989.
22. Rosenberg B: Linear regression with randomly dispersed parameters. Biometrika 60: 65-72, 1973.
23. Strenio JF, Weisberg HI, and Bryk AS: Empirical Bayes estimation of individual growth-curve parameters and their relationship to covariates. Biometrics 39: 71-86, 1983.
24. Morris CN: Parametric Empirical Bayes inference: theory and applications. J Am Stat Assoc 78: 47-65, 1983.
25. Raudenbush SW, and Bryk AS: Empirical Bayes metaanalysis. J Educational Behavioral Statistics 10: 75-98, 1985.
26. Lepor H, and Stoner E: Long-term results of medical therapies for BPH. Curr Opin Urol 5: 18-24, 1995.
27. Barry MJ, Williford WO, Chang YC, Machi M, Jones KM, Walker-Corkery E, and Lepor H: Benign prostatic hyperplasia-specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 154: 1770-1774, 1995.
28. Barry MJ, Cockett ATK, Holtgrewe HL, McConnell JD, Sihelnik SA, and Winfield HN: Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol 150: 351-358, 1993.
29. Girman CJ, Jacobsen SJ, Guess HA, Oesterling JE, Chute CG, Panser LA, and Lieber MM: Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J Urol 153: 1510-1515, 1996.
30. Roehrborn CG, Chinn HKW, Fulgham PF, Simpkins KL, and Peters PC: The role of transabdominal ultrasound in the preoperative evaluation of patients with benign prostatic hypertrophy. J Urol 135: 1190-1193, 1986.
31. Oesterling JE, Jacobsen SJ, Chut CG, Guess HA, Girman CJ, Panser LA, and Lieber MM: Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 270: 860-864, 1993.
32. Abrams P: New words for old: lower urinary tract symptoms for "prostatism." BMJ 308: 929-930, 1994.
33. Boyarski S, Jones G, Paulson DF, Prout G Jr: A new look at bladder neck obstruction by the Food and Drug Administration regulators: guide lines for investigation of benign prostatic hypertrophy. Trans Am Assoc Genitourin Surg 68: 29-32, 1976.
34. Bolognese JA, Kozloff RC, Kunitz SC, Grino PB, Patrick DL, and Stoner E: Validation of a symptoms questionnaire for benign prostatic hyperplasia. Prostate 21: 247-254, 1992.
35. Barry NJ, Fowler FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett ATK, and the Measurement Committee of the American Urological Association: The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 148: 1549-1557, 1992.